Dedicated to creating life-changing medicines for people with
limited or no options.

Research and Development

As the field of science has grown, so have our R&D capabilities. We actively explore revolutionary drug options ranging from small molecule advancements to biologics, and novel compounds within hematology/oncology and sleep medicine. This dynamic approach has allowed us to shepherd new medicines to market — from late-stage discovery through clinical development and regulatory approval.

All of these advancements are a reflection of our continued investment in an evolving and growing research and development focus.

Pipeline

PRE-CLINICAL
Oxybate
once-nightly formulation

CombiPlex
Solid tumors candidate I

CombiPlex
Hem/onc exploratory activities

Asparaginase
ALL/other hematological malignancies

Recombinant Pegaspargase
Hematological
malignancies

Defibrotide
Exploratory activities

Exosome NRAS candidate
Hematologic malignancies§

Exosome STAT3 candidate
Hematologic malignancies§

Exosome-based candidates
Solid tumors/Hematologic malignancies§

PHASE 1
CPX-351 + gemtuzumab
R/R AML or HMA Failure
MDS* (ages ≥18)

CPX-351 + venetoclax
Low intensity dosing for unfit AML†

IMGN779
CD33+ AML

IMGN632
CD123+ hematological malignancies

PHASE 2
Solriamfetol
EDS in Parkinson’s disease

Defibrotide
Prevention of acute GvHD

Defibrotide
Treatment of TA-TMA†

Defibrotide
Prevention of CAR-T associated neurotoxicity†

CPX-351 + venetoclax
de novo or R/R AML*

CPX-351
MDS**†

CPX-351
R/R AML**

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
idiopathic hypersomnia

Defibrotide
Prevention of VOD

CPX-351
AML or HR-MDS (AML19) (ages 18-60)**‡

CPX-351
AML or HR-MDS (AML18) (ages ≥60)**‡

REGULATORY
Solriamfetol EU
EDS in OSA or narcolepsy

Solriamfetol U.S.
EDS in OSA and narcolepsy

Sleep
Hematology / Oncology
Opt-in Opportunity
*Jazz & MD Anderson Cancer Center Study
** Key Cooperative Group Study
Planned
Study Sponsor – Cardiff University
§Jazz & Codiak BioSciences collaboration
Jazz & ImmunoGen collaboration

Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.